Longboard Pharmaceuticals, Inc.
CIK 0001832168
Revenue (TTM)
—
Q3 Nov 2024
Net Income (TTM)
−$74.25M
−23.8% YoY
Q3 Nov 2024
EPS Diluted (TTM)
−$2.16
+6.6% YoY
Q3 Nov 2024
Gross Margin
—
Q3 Nov 2024
Operating Margin
—
Q3 Nov 2024
Net Margin
—
Q3 Nov 2024
Free Cash Flow (TTM)
−$46.05M
Q3 Nov 2024
Cash
$27.61M
Q3 Nov 2024
Total Debt
—
Q3 Nov 2024
Shares Outstanding
39.05M sh
Q3 Nov 2024
Revenue & Net Income
EPS (Diluted)
Cash Flow
Revenue Growth (YoY)
No data available for this metric.